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Abstract: Aripiprazole is a second-generation antipsychotic with a unique pharmacologic 
receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. 
This article reviews the evidence supporting treatment of adults with bipolar I disorder using 
aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramus-
cular agent for agitation in manic patients. Results from one of the longest bipolar maintenance 
trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic 
relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling 
bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s 
place in therapy for bipolar mania will be covered.
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Introduction
The management of acute mania presents challenges to clinicians that extend beyond 
simple symptomatic reduction. Clearly, early recognition of manic states and early 
intervention pharmacologically is necessary in order to resolve the affective disturbance 
and to avoid serious negative consequences that may result from out-of-control manic 
behaviors. Fortunately, a growing number of antimanic medication treatment options 
have become available over the past decade which has fortified the armamentarium 
from which clinicians may select and patients may choose effective antimanic therapy. 
However it is quite important that a more far-sighted approach to managing acute mania 
is undertaken given the recurrent and sometimes chronic nature of bipolar disorder. 
While acutely treating mania, clinicians must take into consideration not only short-
term efficacy and tolerability but begin laying the foundation of a safe and effective 
long-term prevention strategy.
This article seeks to review the treatment and prevention of mania in bipolar I 
disorder with a focus on aripiprazole. Only data related to adult bipolar disorder from 
large, randomized and controlled clinical trials will be included with an emphasis 
on studies related to aripiprazole’s approved usages in the United States and clinical 
implications and patient-centered perspectives.
The emergent use of atypical antipsychotics  
for mania
Manic episodes are often medical emergencies that require hospitalization in order to 
rapidly address abnormal affective symptomatology, restore behavioral control and 
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protect the individual with bipolar disorder and others from 
the consequences related to impulsive and often dangerous 
actions. Prior to the approval of olanzapine for the manage-
ment of acute mania by the US Food and Drug Administration 
(US FDA) in 2000, only lithium, divalproex and chlorpro-
mazine carried an anti-manic indication. Since then four 
other atypical or second-generation antipsychotics (SGAs) 
have received US FDA approval for the management of 
acute bipolar mania – risperidone (2003), quetiapine (2004), 
ziprasidone (2004), and aripiprazole (2004). Evidence of 
longer-term stabilization of mood provided by olanzapine, 
aripiprazole, and quetiapine (adjunctively with lithium 
or divalproex) – particularly against manic relapses and 
recurrences – led not only to their US FDA approval as main-
tenance therapies for bipolar I disorder but the emergence 
of atypical antipsychotics as common, first-line pharmaco-
therapies in clinical practice for the treatment and prevention 
of mania. Table 1 summarizes the strength of available data 
and US FDA indications for the antipsychotic medica-
tions in the treatment of mania and prevention of relapse 
in bipolar I disorder.1 In addition to these antipsychotics, 
it should be noted that other mood stabilizers not reviewed 
here carry US FDA indications against mania (lithium, 
divalproex, divalproex extended-release, carbamazepine) 
and for maintenance treatment of bipolar I disorder (lithium; 
lamotrigine – primarily for depressive relapse).
An overview of the pharmacology  
of aripiprazole
Aripiprazole is an SGA that belongs to the quinolinone class, 
available since the end of 2003, and available in a wide variety 
of formulations (tablets, oral solution, oral-disintegrating 
tablets, short-acting intramuscular injectable). To date, studies 
have consistently confirmed that this SGA is reasonably 
well tolerated, with low metabolic risks (induction of type 2 
diabetes, weight gain, hyperlipidemia), little sedation, and 
generally mild extrapyramidal side effects (EPS).
As with psychosis, central dopaminergic hyperactivity 
has long been implicated as a causative factor in acute mania.2 
Dopamine D2 receptor antagonists, both typical and atypical 
antipsychotics, presumably exert both antipsychotic and 
antimanic effects by dampening hyper-dopaminergic brain 
activity. Although similar in many ways to other SGAs, 
aripiprazole’s pharmacologic mechanism of action is unique 
among the atypical antipsychotics due to a complex receptor 
profile.3–5 Its profile of partial agonist action at several G-protein 
coupled receptors (postsynaptic dopamine (D2), presynaptic 
dopamine autoreceptors, 5-HT1A) and antagonism at others 
Table 1 Antipsychotic drugs for bipolar mania and maintenance, US-FDA indications and strength of data
Agent Acute mania Maintenance
US-FDA approved? Strength of data US-FDA approved? Strength of data
SGAs
  Aripiprazole Yesa A yes Ab
  Asenapine no A no n/a
  Olanzapine yes1 A yes A
  Paliperidone no n/a no n/a
  Quetiapine yesa,c A yesa A
  risperidone yes1 A no n/a
  Ziprasidone yes A no n/a
Typical antipsychotics
  Chlorpromazine yes B no n/a
  Haloperidol no A no n/a
  Perphenazine no n/a no negative
aadditionally indicated as adjunct to lithium or valproate; bno effectiveness against bipolar depression; camong the approved second-generation antipsychotics (SGAs) for acute 
mania, the only agent that does not also carry indication for mixed episodes.
Strength of data on basis of a modified POST method.1
Level A: Good research-based evidence, supported by at least one-placebo-controlled study of sufficient magnitude.
Level B: Fair research-based evidence, from at least one randomized, double-blind controlled trial but does not fulfill the level A criteria fully (eg, no placebo control or small 
sample size).
Negative: negative data; n/a: none available.
United States Food & Drug Administration (US FDA) data can be accessed at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/Neuropsychiatric Disease and Treatment 2009:5 281
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(5-HT2A) marks aripiprazole as the first functionally selective 
atypical antipsychotic. Lacking the conventional D2 receptor 
antagonism characteristics of other antipsychotics, aripipra-
zole most likely exerts antimanic efficacy by way of partial 
dopamine D2 receptor agonist activity, thus lowering intrinsic 
and excessive dopamine neurotransmission.6 In addition, partial 
agonism at the dopamine D3 receptor may also contribute to 
aripiprazole’s therapeutic action in bipolar disorder.7
Positron emission tomography (PET) studies support the 
proposed mechanism of receptor action for aripiprazole as 
a partial dopamine agonist.8,9 Aripiprazole occupied 70% to 
80% of striatal dopamine receptors in healthy subjects at doses 
of 2 mg/day, with dopamine occupancy at 95% when the dose 
was increased to 30 mg/day while EPS was not observed. A 
pure agonist would likely induce EPS at such high dopamine 
receptor occupancy levels. Aripiprazole has minimum affinity 
for histamine, muscarinic and alpha-1 adrenergic neurorecep-
tors which may explain the excellent tolerability of the drug 
in terms of sedation, heart rate and weight gain.3,10
Aripiprazole is rapidly absorbed and demonstrates 
linear pharmacokinetics with a mean elimination half-life 
of 75 hours, allowing for single daily dosing. The drug is 
highly protein bound in plasma. Elimination of aripiprazole 
occurs chiefly though hepatic metabolism via cytochrome 
P450-2D6 and 3A4. Clinically significant alterations in arip-
iprazole plasma levels may occur when co-administered with 
3A4 inducers (ie, carbamazepine), inhibitors (ie, fluvoxamine, 
ketoconazole), or substrates (ie, nefazodone, haloperidol). 
Aripiprazole has safely been co-administered with valproic 
acid and lithium.11
Efficacy studies of aripiprazole  
for bipolar mania
Aripiprazole is approved by the US FDA for the management 
of acute manic or mixed episodes of bipolar disorder in adults, 
either as monotherapy or as an adjunctive therapy to either 
lithium or valproate. Aripiprazole monotherapy is indicated for 
maintenance treatment of manic and mixed episodes associated 
with bipolar I disorder. Additionally, aripiprazole has efficacy 
in the acute treatment of agitation associated with manic or 
mixed states. This article will not review aripirazole’s approval 
for mania in children ages 10 to 17, for schizophrenia, or as 
adjunctive therapy for unipolar major depression.
Aripiprazole – monotherapy treatment  
of mania
The efficacy of aripiprazole monotherapy in the treatment 
of acute manic or mixed episodes was established in four 
3-week, placebo-controlled trials (n = 268; n = 248; n = 480; 
n = 485) in hospitalized patients who met criteria for bipolar I 
disorder (US FDA Prescribing Information: http://www.
accessdata.fda.gov/scripts/cder/drugsatfda/). Patients with 
or without psychotic features were included in all four trials, 
while patients with or without rapid cycling were included 
in two of the studies. Across all studies the primary outcome 
was change in degree of manic symptomatology as measured 
by the Young Mania Rating Scale (YMRS) with secondary 
outcome measurements including the Clinical Global 
Impression – Bipolar (CGI-BP) Scale. Aripiprazole was 
superior to placebo in the reduction of YMRS total score and 
CGI-BP Severity of Illness score for mania. As noted in the 
review by Garcia-Amador and colleagues, one unpublished 
monotherapy, placebo-controlled study was negative.12 
Among the positive studies, aripiprazole monotherapy was 
associated with a 10% to 20% greater response than placebo 
in the treatment of manic and mixed episodes.13–15
The seminal aripiprazole monotherapy trial by Keck and 
colleagues for bipolar mania utilized a starting daily dose of 
30 mg aripiprazole or placebo while allowing for reduction to 
15 mg/day for tolerability.13 In this 3-week study, aripiprazole 
monotherapy demonstrated significantly greater efficacy 
compared with placebo in reduction of total YMRS scores 
from baseline to study endpoint (mean change in YMRS: 
aripiprazole -8.2, placebo -3.4). Statistically significant 
separation between active treatment and placebo effects on 
manic symptoms was noted as early as Day 4. Using the 
standard definition of antimanic response – reduction of 
baseline YMRS by 50% – aripiprazole monotherapy was 
associated with a 40% response rate, statistically superior 
to the 19% response rate observed with placebo. The mean 
aripiprazole dose at endpoint was 27.9 mg/day.
In a separate study of aripiprazole monotherapy 
employing similar design, 53% of aripiprazole-treated 
patients with bipolar I mania or mixed state responded to 
treatment by end of the 3-week placebo controlled study 
at a mean dose of 28 mg/day.15 A statistically significant 
lower placebo response rate of 32% was observed in this 
study compared with active treatment. This study also dem-
onstrated early onset of antimanic effects with aripiprazole 
monotherapy compared with placebo, again with separation 
between treatment arms on Day 4 and sustained throughout 
the 3-week study.
A post-hoc analysis of these two studies found that 
the antimanic response to aripiprazole was independent of 
baseline level of agitation, suggesting a specific antimanic 
effect.16 In a separate post-hoc analysis of pooled efficacy Neuropsychiatric Disease and Treatment 2009:5 282
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data from these two studies, Frye and colleagues exam-
ined individual manic symptoms measured by the 11-item 
YMRS to determine how individual symptom improvement 
relates to overall improvement in patients with bipolar I 
disorder with an acute manic or mixed episode.17 Aripipra-
zole monotherapy (n = 259) significantly improved 10 of 
11 YMRS manic symptom domains, statistically separating 
from placebo treatment (n = 254) on all YMRS line items 
with the exception of sexual interest by study endpoint 
(Figure 1). The antimanic effect of aripiprazole therefore 
was diffuse and widespread among manic patients and across 
various manic symptom domains, with the YMRS line items 
ranked with the highest percent change over placebo being 
disruptive–aggressive behavior (34%), insight (29%), and 
irritability (28%).
Further post-hoc analysis of these pooled data was 
conducted to determine whether any treatment differences 
existed among subpopulations of patients with acute manic 
or mixed episodes of bipolar I disorder given aripiprazole 
or placebo.18 Aripiprazole significantly reduced mean 
YMRS total scores at end point compared with placebo 
irrespective of patient age, sex, or severity of illness. Impor-
tantly, aripiprazole also evidenced antimanic superiority 
over placebo among bipolar I patients with mixed or 
manic episodes, with or without psychotic features, or 
with a history of rapid or non-rapid cycling (p  0.01 for 
each subpopulation). These results support efficacy of 
aripiprazole across a broad range of bipolar subpopula-
tions often associated with treatment resistance, such as 
psychotic or rapid cycling patients experiencing manic or 
mixed episodes of bipolar I disorder.
Vieta and colleagues compared aripiprazole and haloperidol 
monotherapy in a 12-week study of 347 patients with bipolar 
I disorder experiencing an acute manic or mixed episode.19 
This double-blind, randomized trial assigned patients to either 
aripiprazole or haloperidol monotherapy with the primary 
outcome measured as number of patients in response (50% 
reduction in YMRS) and still on treatment at week 12 – repre-
senting an “effectiveness measure of response.” Aripiprazole 
was initiated at 15 mg/day and haloperidol at 10 mg/day, with 
dosage increased to 30 mg/day and 15 mg/day, respectively, 
at week 1 or 2 in patients showing poor response; reduction 
to initial starting dose was permitted for tolerability reasons if 
necessary with those patients not able to tolerate the minimum 
starting daily dosages discontinued from study. Both active 
treatments produced considerable and early reductions in 
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2. Increased motor activity
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5. Irritability
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7.   Language-thought disorder
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Figure 1 Mean changes in individual  YMrS line items of patients with an index of manic or mixed episode. aitem range of 0–4 for elevated mood, increased motor activity/energy, 
sexual interest, sleep, language/thought disorder, appearance, and insight. item range of 0–8 for irritability, speech, content, and disruptive/aggressive behavior (2).
aPooled data from 2 placebo-controlled trials (LOCF). *p  0.001, †p = 0.002, ‡p = 0.001, §p = 0.003, ||p = 0.006.
reproduced with permission from Frye MA, Eudicone J, Pikalov A. et al.   Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line 
analysis from two, randomized, double-blind, placebo-controlled trials. J Clin Psychopharmacol. 2008;28:243–245.17 Copyright © 2007 Lippincott Williams & Wilkins.Neuropsychiatric Disease and Treatment 2009:5 283
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manic symptomatology with no statistically significant dif-
ferences in effectiveness between the two groups at week 3: 
a 50.9% response with aripiprazole and 42.6% response with 
haloperidol (p = 0.126), as depicted in Figure 2. However, at 
week 12 significantly more patients randomized to aripipra-
zole were responders and still on therapy (49.7%) compared 
with those on haloperidol (28.4%) (p  0.001). Patients 
given haloperidol during this study were nearly twice as likely 
as those given aripiprazole to discontinue their medication, 
primarily due to adverse events associated with treatment. 
Extrapyramidal symptoms occurred in 36% of haloperi-
dol-treated patients compared to 9% of aripiprazole-treated 
patients. The results of this study suggest that aripiprazole’s 
greater sustained response rates and better tolerability make it 
a more effective treatment for acute mania than haloperidol.
Aripiprazole has also been studied as monotherapy for 
bipolar I mania/mixed state with a randomized, double-blind, 
placebo- and lithium-controlled trial.20 Patients were 
randomized to aripiprazole (15–30 mg/day; n = 155), placebo 
(n = 165) or lithium (900–1500 mg/day; n = 160) for 3 weeks, 
with continuation of blinded active treatment for an additional 
9 weeks. Aripiprazole demonstrated significantly greater 
improvement than placebo in mean YMRS total score from 
baseline to Day 2 (-4.3 vs -2.8; p = 0.003), and up to week 
3 (-12.6 vs -9.0; p  0.001). Significant improvement in 
YMRS total score was first observed with lithium versus 
placebo at week 3 (-12.0 vs -9.0; p = 0.005). Improvements 
in YMRS total score were sustained through week 12 for 
both aripiprazole (–14.5) and lithium (–12.7). Response 
rates at week 3 were significantly higher with aripiprazole 
(46.8%) and lithium (45.8%) than placebo (34.4%; both 
p  0.05); growing to week 12 with aripiprazole (56.5%) and 
lithium (49.0%). Aripiprazole led to statistically significant 
improvement of acute mania within 2 days, continuing over 
3 weeks and maintained over 12 weeks. The magnitude of 
improvement in manic symptomatology was similar with 
aripiprazole and lithium through 12 weeks of treatment.
In summary, aripiprazole monotherapy at doses of 
15 to 30 mg/day is efficacious in the treatment of acute 
manic and mixed states associated with bipolar I disorder. 
As an antimanic agent it compares favorably with lithium 
and haloperidol, with faster onset of action than lithium and 
with greater effectiveness of response than haloperidol.
Aripiprazole – adjunctive treatment  
of mania
A recent multicenter, randomized, placebo-controlled 
study of adjunctive aripiprazole added to either lithium or 
valproate treatment in manic/mixed bipolar I patients partially 
nonresponsive to lithium/valproate monotherapy has been 
reported.21 This study consisted of 3 phases: a screening 
phase, an open-label treatment phase, and a double-blind 
phase. During the Phase 1 screening period, medications 
other than lithium or valproate were discontinued; 
patients were required to achieve serum levels of lithium 
(0.6 to 1.0 mmol/L) or valproate (50–125 µg/mL) in the 
therapeutic range yet remain manic at end of screening 
(YMRS  16). In Phase 2, open-label lithium or valproate 
was continued as monotherapy for 2 weeks. Those patients 
with partial nonresponse to mood stabilizer monotherapy at 
the end of Phase 2, defined as YMRS persisting at 16 with a 
decrease of 25% between Phases 1 and 2, were eligible for 
Phase 3 random assignment to double-blind adjunctive arip-
iprazole or placebo for 6 weeks. Adjunctive aripiprazole was 
initiated at 15 mg/day and could be increased to 30 mg/day 
after 1 week depending on clinical response or tolerability.
Adjunctive aripiprazole compared with placebo added to 
lithium or valproate was associated with significantly greater 
reduction in manic symptomatology as measured by YMRS 
at week 1 of double-blind treatment and at all study points 
through week 6. Six of 11 YMRS items were significantly 
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Figure 2 response rates to monotherapy treatment with aripiprazole and haloperidol at 
weeks 3 and 12 among patients with bipolar i disorder, manic or mixed at baseline.
***p  0.001 versus haloperidol.
reproduced with permission from   Vieta e, Bourin M, Sanchez r, et al. effectiveness of 
aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 
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improved with adjunctive aripiprazole relative to placebo: 
elevated mood, sexual interest, irritability, speech, disruptive/
aggressive behavior and insight. Response rates with adjunctive 
aripiprazole were higher than placebo, separating statistically 
from placebo at week 5 and remaining significantly greater 
at week 6, 62.8% versus 48.5%, respectively (p  0.01). 
Remission, defined as total YMRS  12, was observed in a 
significantly larger number of patients receiving adjunctive 
aripiprazole compared with placebo at weeks 1, 3, 4, 5, and 6; 
at week 6, the remission rate was 66.0% for adjunctive aripipra-
zole and 50.8% for placebo (p  0.01). In addition, there was 
significant reduction in the emergence of depression as well as 
improvement in psychosocial functioning among the adjunctive 
aripiprazole group compared with placebo in this study.
Aripiprazole – acute agitation associated 
with bipolar mania
In a multicenter clinical trial, 301 agitated patients with 
bipolar I disorder in manic or mixed state were randomized 
in double-blinded fashion to receive intramuscular (IM) 
aripiprazole (9.75 or 15 mg IM), IM lorazepam (2 mg) or 
IM placebo. Up to 3 injections in the first 24 hours were 
permitted.22 Based on mean change in Positive and Negative 
Syndrome Scale Excited Component scores, both doses of IM 
aripiprazole as well as IM lorazepam demonstrated significant 
improvement in agitation 2 hours post-injection compared 
with IM placebo. Oversedation during the first 2 hours after 
injection was significantly less with IM aripiprazole 9.75 mg 
and IM placebo compared with IM aripiprazole 15 mg and 
IM lorazepam. These results suggest that IM aripiprazole can 
be used to quickly and effectively reduce agitation in manic 
patients, with a tolerability advantage for the 9.75 mg IM dose 
over IM aripiprazole 15 mg or IM lorazepam 2 mg.
Aripiprazole – prevention of mania
Keck and colleagues conducted an initial 26-week 
placebo-controlled, double blind study that evaluated the 
long-term efficacy of aripiprazole in the prevention of mood 
episodes associated with bipolar I disorder.22 This study was 
later extended by 74 weeks for a total of 100 weeks, thus 
comprising the longest maintenance study of bipolar disor-
der to date.14 The study employed an enriched design, with 
patients first completing a stabilization treatment phase which 
included aripiprazole as therapy for an acute manic or mixed 
episode. During the 6- to 18-week stabilization phase, patients 
were given aripiprazole 15 to 30 mg/day and were eligible to 
enter the randomized maintenance study once remission of the 
acute mania/mixed episode was achieved (defined by YMRS 
total scores 10 in 4 consecutive weeks or during 6 weeks, 
plus the absence of depression). The stabilized patients 
were then randomly assigned to double-blind treatment with 
aripiprazole or placebo and followed over 100 weeks with 
a primary study endpoint of relapse to any mood episode. 
Time to any relapse was significantly longer with aripiprazole 
monotherapy compared with placebo (p = 0.011). Further 
analysis demonstrated that this statistical superiority was 
present for aripiprazole over placebo only for the prevention 
of manic relapses; there were no significant differences in 
depressive relapses between treatment groups. Nearly half of 
the patients receiving aripiprazole monotherapy in the study 
were on 15 mg/day at end of study.
In a post-hoc analysis of this 100-week maintenance study, 
the impact of aripiprazole on the course of rapid cycling 
bipolar disorder was examined in comparison to placebo.23 
Among the small sample of patients (n = 28) with rapid 
cycling bipolar disorder who were initially stabilized from 
a manic or mixed episode during open label treatment that 
included aripiprazole and went on to be randomized to double-
blinded treatment, time to any mood relapse was significantly 
longer with aripiprazole monotherapy compared with placebo 
at week 26 (p = 0.033) and at week 100 (p = 0.017).
Aripiprazole monotherapy is effective in the long-term 
treatment of bipolar disorder, with more robust prophylaxis 
against manic relapses than depressive relapses among 
recently manic patients who were stabilized acutely with arip-
iprazole. There is also evidence to suggest that aripiprazole 
monotherapy is effective in the prevention of relapse among 
patients with rapid cycling, which may represent a more 
refractory form of bipolar disorder with greater morbidity 
than non-rapid cycling illness. Long-term prevention of 
relapse among rapid cycling bipolar patients using a combi-
nation of aripiprazole with a second mood stabilizer has not 
been systematically investigated. Such an effort is warranted 
given these findings and an emerging consensus that patients 
with bipolar disorder on monotherapy, if followed for suf-
ficiently long periods, will eventually require adjunctive or 
combination treatment to maintain a full remission.24
Safety and tolerability  
of aripiprazole
In the studies reviewed here with aripiprazole among 
patients with bipolar disorder for acute treatment of mania 
and for prevention of relapse, the drug was generally well 
tolerated. The most commonly observed adverse reactions 
associated with the use of aripiprazole in adult patients with 
bipolar disorder are noted in Table 2. Of particular clinical Neuropsychiatric Disease and Treatment 2009:5 285
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concern with the use of any antipsychotic agent, including 
aripiprazole and other SGAs, is the risk of EPS, weight gain, 
induction of type II diabetes and elevation of lipids.
The incidence of EPS, including akathisia, is thought to 
be relatively low with aripiprazole and other SGAs in com-
parison with conventional antipsychotics. The rates of EPS 
reported in randomized controlled clinical trials of SGAs 
in bipolar disorder range between 5% and 15%, although 
this low figure has been challenged as non-representative 
of the rates observed in the “real world” clinical setting.25 
A recent review of antipsychotic-induced EPS relative to 
placebo from large randomized controlled trials in bipolar 
disorder and schizophrenia found that patients with bipolar 
disorder were more vulnerable to acute EPS than those with 
schizophrenia, even with SGAs.26 It should be noted that 
this analysis revealed that among patients with bipolar dis-
order who experienced EPS from any antipsychotic agent, 
its occurrence was much more likely during the depressive 
phase than when manic. However, the incidence of akathisia 
was significantly increased in manic patients receiving 
aripiprazole compared with other SGAs.
In the 100-week maintenance study of aripiprazole 
monotherapy, the mean weight change from baseline 
was +0.4 kg (± 0.8 kg) with aripiprazole and -1.9 kg 
(± 0.8 kg) with placebo.14 However, some patients may be 
more sensitive to the risk of weight gain with 20% (12/60) 
of the aripiprazole-treated patients in this long-term study 
gaining clinically significant weight (+7% from baseline) 
compared with only 5% (3/61) of the placebo-treated patients 
(p = 0.01). Further analysis of mean weight change in this 
study by body mass index (BMI) at baseline is summarized 
in Table 3. No significant difference in weight change was 
observed between aripiprazole and placebo for patients in 
both the low baseline BMI (23 kg/m2) and high baseline 
BMI (27 kg/m2) categories at study end point.
The data from this long-term aripiprazole study also pro-
vide valuable information regarding the incidence of other 
clinically important changes in metabolic risk factors with 
treatment. No statistically significant differences were found 
in the change from baseline to week 100 in combined fasting 
and nonfasting glucose, high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol, total cholesterol, or 
triglycerides with aripiprazole treatment. In addition, there 
were no significant differences in the incidence of abnormal 
lipid or glucose levels between groups over the 100 weeks of 
treatment. These findings are consistent with the consensus 
statement from the American Diabetes Association/American 
Psychiatric Association/American Association of Endo-
crinologists collaborative conference on antipsychotic drugs 
and obesity and diabetes.27 Their summary of scientific evi-
dence indicated that among the SGAs both aripiprazole and 
ziprasidone carried the lowest risk for induction of weight 
gain, diabetes and lipid disorders.
There are case reports in the literature of aripiprazole 
induction of tardive dyskinesia or dystonia,28,29 and neu-
roleptic malignant syndrome.30 Aripiprazole has not been 
associated with elevation of prolactin31 and has been reported 
to reverse hyperprolactinemia due to other antipsychotics or 
prolactinomas.32 The risk for agranulocytosis and seizures is 
very low, although two case reports of isolated seizures on 
aripiprazole have been published.33,34
Aripiprazole – patient-focused 
perspectives
Increasingly, patients with bipolar disorder and their clinicians 
have come to recognize that the best medication management 
Table 2 Commonly observed adverse reactions associated with 
the use of aripiprazole in patients with bipolar i disorder (incidence 
of 5% and at least twice the rate of placebo)a
Indications Aripiprazole (%) Placebo (%)
Monotherapy for mania
  Akathisia 13 4
  Sedation 8 3
  Tremor 6 3
  restlessness 6 3
  extrapyramidal disorder 5 2
Adjunctive for mania
  Akathisia 19 5
  insomnia 8 4
  extrapyramidal disorder 5 1
  iM for agitation
  Nausea 9 3
Maintenanceb
  Tremor 9 1
  Akathisia 8 1
  Dry mouth 8 1
  Hypertension 8 4
  Weight gain 6 0
  Vaginitis 6 0
  Flu syndrome 5 0
  Pharyngitis 5 2
  Abnormal thinking 5 2
aUS FDA Prescribing information for Abilify® (aripiprazole) available at: http://www.
accessdata.fda.gov/scripts/cder/drugsatfda/ or http://packageinserts.bms.com/pi/
pi_abilify.pdf
bKeck et al.14Neuropsychiatric Disease and Treatment 2009:5 286
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strategies involve not just treatment of the acute episodes of 
mania but implementation of effective prevention early in 
the course of the illness as well as factoring in individual 
patient preferences and concerns. Several patient-focused 
perspectives and issues must be considered.
Acutely manic patients often lack insight into the pres-
ence of an active mood disorder and the need for treatment, 
with little improvement in level of insight upon discharge 
from psychiatric inpatient hospitalization and despite marked 
improvement in symptoms.35 Impaired insight among patients 
with bipolar I disorder has been reported in 47% of remitted 
and 94% of symptomatic patients,36 and is more commonly 
found in patients with bipolar disorder than those with uni-
polar major depression or anxiety disorders.37 Manic patients 
with psychotic features are more likely to have poor insight 
into the need for treatment.38 Impaired insight, particularly 
into need for treatment more so than into diagnosis, has a 
negative impact on clinical outcome.37,39 Conversely, patients 
with bipolar disorder who have higher levels of insight may 
be at increased risk for suicide and more commonly report 
poorer overall quality of life.40,41
The cause for impaired insight is unknown and presents 
a very common problem during treatment of mania and 
in longer term maintenance. Although poorly studied in 
bipolar disorder, stigma related to mental illness as well as 
the stigmatizing effects of antipsychotic medications likely 
plays a significant role in non-adherence and may be difficult 
to tease apart from trouble with patient insight.42 Evidence 
suggests that improving level of insight in patients with 
bipolar disorder represents an opportunity to improve adher-
ence with treatment and ostensibly improve outcomes.43 The 
negative effects of stigma and insight impairments can only 
be counteracted when they are addressed by caring clinicians 
through better understanding of individual patient factors and 
with support from the family and society as a whole. Psych-
oeducation, family-focused and other psychotherapies must 
all be utilized to support medication management efforts.
Patients in need of medication therapy, including those 
with bipolar disorder, ask practical questions related to 
their decision to take medications such as aripiprazole: “Do 
I have to take medication?”; “Will it work?”; “Will I have 
side effects?”; “Will I have to take multiple medications?”; 
“Will I be able to return to work?”; and, “How long will I 
have to take it?”
The availability of an injectable form of aripiprazole 
provides a therapeutic option for those patients with bipolar 
disorder who are manic and agitated. In such a context, 
insight is often impaired, and the use of IM medication is 
often necessary for the protection of the patient and others. 
With rapid and effective control of acute manic symptoms, 
clinical experience suggests that patients are often better 
able to engage in a therapeutic alliance and to have informed 
consent discussions about therapeutic options to treat the 
mania and to plan for prevention of future episodes.
The data reviewed in support of aripiprazole for the 
treatment and prevention of mania allows clinicians to 
discuss the risks and benefits associated with aripiprazole 
therapy. Dosing aripiprazole appropriately is important, as 
a balance between rapid antimanic effects and avoidance of 
side effects is obviously desirable. Although combination 
therapy for acute mania if often considered first-line for many 
manic patients, the evidence supports the use of aripiprazole 
as either monotherapy or as an adjunct to a mood stabilizer 
such as lithium or valproate. Generally, aripiprazole should be 
started at 15 mg/day for acute mania, although the presence of 
concomitant antimanic therapy or patient history of medication 
sensitivity may dictate starting at a lower dose. For severely 
manic patients, starting with 30 mg/day may be necessary. 
Adjusting the dose during the first few weeks of aripiprazole 
therapy should then be based on response and tolerability.
Prompt attention to and effective management of 
treatment emergent side effects that appear early in the 
course of treating mania with aripiprazole is important. 
Dosage reduction may be necessary should akathisia 
develop. Akathisia may also be treated with beta-blockers, 
benzodiazepines, or anticholinergics. Reducing the dose 
of aripiprazole when nausea or vomiting is encountered as 
a side effect and later returning to the target dose is often 
Table 3 Mean weight change by body mass index (BMi) at baseline for aripiprazole monotherapy versus placebo in a 100-week maintenance 
study of recently manic patients with bipolar i disorder
BMI (kg/m2) Aripiprazole (kg) Placebo (kg) p value
23 +1.86 –1.91 ns
23–27 +3.04 –2.59 0.025
27 –0.77 –1.81 ns
Abbreviations: ns, nonsignificant; p  0.05.Neuropsychiatric Disease and Treatment 2009:5 287
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helpful, otherwise conventional antiemetic medications 
can be utilized. Insomnia secondary to aripiprazole can be 
minimized by taking the medication in the morning only and 
may also be ameliorated through the use of benzodiazepines 
or hypnotics. These and other practical guidelines can be used 
to minimize side effect burden for patients on aripiprazole 
and to maximize its efficacy.44
With long-term aripiprazole therapy, clinicians should be 
vigilant in their monitoring for metabolic perturbations that 
may be related to treatment. Although the risk for weight 
gain, diabetes and hyperlipidemia appears to be low with 
this SGA, some patients may be predisposed to these adverse 
events and so all patients should be routinely weighed and 
have laboratory assessments of fasting glucose and lipids. 
The frequency of such safety monitoring should be tailored 
to each patient’s individual need based on personal and 
family risk factors. More specific guidelines for monitoring 
patients on aripiprazole and other SGAs can be found in the 
literature.24
Patients and their families should be continuously 
educated about the recurrent and sometimes chronic nature 
of bipolar disorder and the need for long-term medication 
and safety monitoring. The appropriate use of psychothera-
pies and community support groups should be encouraged, 
particularly given increasing evidence of benefit for delaying 
time to relapse. Symptomatic and syndromic recovery from 
acute mania is likely with adherence to medications such as 
aripiprazole, while full functional recovery and cautious pre-
ventive treatment should be the ultimate goal for all patients 
with bipolar disorder.
Conclusions/place in therapy
Aripiprazole is an effective and generally well-tolerated 
medication in the treatment and prevention of mania in 
bipolar I disorder. Its rapid onset of action for acute mania, 
either as monotherapy or in combination with a mood stabi-
lizer, the availability of a fast-acting injectable formulation 
and excellent tolerability position this SGA as a first-line 
agent in the treatment of mania. The results from a 100-week 
study of aripiprazole for the prevention of bipolar I episodes 
represent the longest maintenance study since early lithium 
trials and support the use of aripiprazole as maintenance 
treatment, primarily against manic relapses. Given the lack 
of metabolic adverse effects with long-term aripiprazole 
relative to most other SGAs, it should also be considered 
a first-line prevention strategy, especially among bipolar I 
patients with highly recurrent manias. There is also evidence 
to support its long-term use in rapid cycling bipolar disorder 
and sufficient data regarding safety of usage in combination 
with lithium or valproate. As monotherapy, aripiprazole 
should not be considered effective treatment for or prevention 
of bipolar depression. Prescription of aripiprazole for 
management of bipolar disorder should be accompanied 
by appropriate concern for individual patient preferences, 
acknowledgement of the importance of addressing stigma, 
insight and adherence, as well as psychotherapy and 
conservative caution when monitoring for the emergence 
of any treatment-related side effects or adverse events, 
particularly metabolic derangements.
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